Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

NCT ID: NCT02480764

Last Updated: 2019-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 612 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-27
• Study Completion Date: 2017-10-13

Brief Summary

The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.

Detailed Description

The drug being tested in this study is called TAK-491 (azilsartan medoxomil). Azilsartan medoxomil is being tested to treat Chinese people who have essential hypertension. This study will look at change in blood pressure after 8 weeks of treatment in people who take azilsartan medoxomil compared to people who take valsartan.

The study enrolled 612 patients. Prior to the start of study treatment, participants who have not received antihypertensive treatment within 28 days participated in a 2-week -run in period. Upon completion of the run-in period, participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

• azilsartan medoxomil 40 mg
• azilsartan medoxomil 80 mg
• Valsartan 160 mg

All participants were asked to take study medication at the same time each day throughout the study.

This multi-centre trial was conducted in China. The overall time to participate in this study is up to 14 weeks. Participants made 9 visits to the clinic and contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

Conditions

Essential Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Azilsartan medoxomil 40 mg

Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.

Group Type: EXPERIMENTAL

Azilsartan medoxomil

Intervention Type: DRUG

Azilsartan medoxomil tablets

Azilsartan medoxomil Placebo

Intervention Type: DRUG

Azilsartan medoxomil placebo-matching tablets

Valsartan Placebo

Intervention Type: DRUG

Valsartan placebo-matching capsules

Azilsartan medoxomil 80 mg

Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.

Group Type: EXPERIMENTAL

Azilsartan medoxomil

Intervention Type: DRUG

Azilsartan medoxomil tablets

Azilsartan medoxomil Placebo

Intervention Type: DRUG

Azilsartan medoxomil placebo-matching tablets

Valsartan Placebo

Intervention Type: DRUG

Valsartan placebo-matching capsules

Valsartan 160 mg

Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.

Group Type: ACTIVE_COMPARATOR

Valsartan

Intervention Type: DRUG

Valsartan 80 mg capsules

Azilsartan medoxomil Placebo

Intervention Type: DRUG

Azilsartan medoxomil placebo-matching tablets

Valsartan Placebo

Intervention Type: DRUG

Valsartan placebo-matching capsules

Interventions

Azilsartan medoxomil

Azilsartan medoxomil tablets

Intervention Type: DRUG

Valsartan

Valsartan 80 mg capsules

Intervention Type: DRUG

Azilsartan medoxomil Placebo

Azilsartan medoxomil placebo-matching tablets

Intervention Type: DRUG

Valsartan Placebo

Valsartan placebo-matching capsules

Intervention Type: DRUG

Other Intervention Names

TAK-491; Edarbi; Diovan®

Eligibility Criteria

Inclusion Criteria

1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure (SBP) ≥150 and ≤180 mm Hg on Day 1; or the participant has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic SBP ≥150 and ≤180 mm Hg at the Screening Visit and on Day 1.

2. Is a man or woman aged 18 years or older.

3. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

4. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

5. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent through 30 days after last study drug dose.

6. Has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant.

7. Is willing to discontinue current antihypertensive medications on Day -21 or on Day -28 if the participant is on amlodipine or chlorthalidone.

Exclusion Criteria

1. Has a mean, sitting clinic diastolic blood pressure (DBP) greater than 110 mm Hg at Day 1 (after placebo run in).

2. Is non-compliant (less than 70% or greater than 130%) with study medication during placebo run-in period.

3. Has secondary hypertension of any etiology (eg, renovascular disease documented as the cause of hypertension, pheochromocytoma, Cushing's syndrome).

4. Has a history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.

5. Has clinically significant cardiac conduction defects (eg, third-degree atrioventricular block, sick sinus syndrome).

6. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease and hypertrophic obstructive cardiomyopathy (HOCM).

7. Has severe renal dysfunction or disease (based on estimated glomerular filtration rate [GFR] <30 mL/min/1.73 m^2) at Screening.

8. Has known or suspected unilateral or bilateral renal artery stenosis.

9. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or Stage 1 squamous cell carcinoma of the skin).

10. Has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%) at Screening.

11. Has hyperkalemia (defined as serum potassium above the normal reference range of the central laboratory) at Screening.

12. Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level of greater than 2.5 times the upper limit of normal (ULN), active liver disease, or jaundice at Screening.

13. Has any other known serious disease or condition at Screening (or Randomization) that would compromise participant safety, might affect life expectancy, or make it difficult to successfully manage and follow the participant according to the protocol.

14. Has a history of hypersensitivity or allergies to TAK-491 (azilsartan medoxomil), any of its excipients or other angiotension II (AII) receptor blockers (ARBs).

15. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.

16. Is currently participating in another investigational study or is receiving or has received any investigational compound within 30 days prior to the first dose of study medication.

Note: This criterion does not apply to participants who participated in observational studies that lacked an intervention or invasive procedure.

17. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.

18. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within the past 2 years.

19. Is taking or expected to take an excluded medication.

20. Works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]). (Only for participants with ambulatory blood pressure monitoring [ABPM].)

21. Has an upper arm circumference <24 cm or >42 cm. (Only for participants with ABPM.)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Beijing Chao Yang Hospital

Beijing, Beijing Municipality, China

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Beijing Tong Ren Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Fujian Provincial Hospital

Fuzhou, Fujian, China

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Guangdong General Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

The Peoples Hospital of Guangxi Zhuang Autonomous Region

Nanning, Guangxi Zhuang, China

Affiliated Hospital of Hainan Medical University.

Haikou, Hainan, China

Hebei Cangzhou Central Hospital

Cangzhou, Hebei, China

The 4th Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

The Third Xiangya Hospital of Central South University

Changsha, Hu'nan, China

Hunan Province People's Hospital

Changsha, Hunan, China

Zhuzhou Central Hospital

Fuzhou, Hunan, China

Cardiology/Zhong Da Hospital, Southeast University

Nanjing, Jiangsu, China

Nanjing Medical University Affiliated 2nd Hospital

Nanjing, Jiangsu, China

The Affiliated Hospital of Xuzhou Medical College

Xuzhou, Jiangsu, China

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, China

The First Affiliated Hospital of NanChang University

Nanchang, Jiangxi, China

China-Japan Union Hospital of Jilin University

Changchun, Jilin, China

People's Hospital of Liaoning Province

Shenyang, Liaoning, China

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Cardiology/The Second Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

First Affiliated Hospital of Xian Jiaotong University

Xi’an, Shanxi, China

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China

Tianjin Third Central Hospital

Tianjin, Tianjin Municipality, China

TEDA International Cardiovascular Hospital

Tianjin, Tianjin Municipality, China

Countries

China

References

Wu J, Du X, Lv Q, Li Z, Zheng Z, Xia Y, Tang C, Yao Z, Zhang J, Long M, Hisada M, Wu J, Zhou W, Ma C. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. Medicine (Baltimore). 2020 Aug 7;99(32):e21465. doi: 10.1097/MD.0000000000021465.

Reference Type: DERIVED

PMID: 32769878 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

U1111-1159-5579

Identifier Type: REGISTRY

Identifier Source: secondary_id

TAK-491_305

Identifier Type: -

Identifier Source: org_study_id